Get the Stockscreener App
22.89
5.68%
1.23
Pre-market:
23.00
0.11
+0.48%
Catalyst Pharmaceuticals Inc stock is traded at $22.89, with a volume of 1.45M.
It is up +5.68% in the last 24 hours and up +1.46% over the past month.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
See More
Previous Close:
$21.66
Open:
$21.93
24h Volume:
1.45M
Relative Volume:
1.40
Market Cap:
$2.78B
Revenue:
$460.48M
Net Income/Loss:
$142.80M
P/E Ratio:
19.40
EPS:
1.18
Net Cash Flow:
$221.79M
1W Performance:
+5.87%
1M Performance:
+1.46%
6M Performance:
+13.04%
1Y Performance:
+42.79%
1-Day Range:
$21.69
$22.90
1-Week Range:
$20.46
$23.55
52-Week Range:
$14.47
$24.64
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Name
Catalyst Pharmaceuticals Inc
Sector
Industry
Phone
(305) 529-2522
Address
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
22.89 | 2.78B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 123.21B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 31.94B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.00B | 3.32B | -860.46M | -1.04B | -8.32 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Robert W. Baird | Outperform |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Mar-14-24 | Initiated | Citigroup | Buy |
| Mar-07-24 | Initiated | BofA Securities | Buy |
| Dec-21-23 | Initiated | Oppenheimer | Outperform |
| Aug-24-22 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Resumed | Piper Jaffray | Overweight |
| Oct-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-26-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Sep-30-14 | Reiterated | ROTH Capital | Buy |
| Sep-16-14 | Reiterated | ROTH Capital | Buy |
| Sep-15-14 | Reiterated | H.C. Wainwright | Buy |
| Oct-21-13 | Reiterated | Aegis Capital | Buy |
| Sep-24-13 | Initiated | Maxim Group | Buy |
| Sep-06-13 | Reiterated | Aegis Capital | Buy |
| Apr-18-13 | Initiated | Aegis Capital | Buy |
| Aug-27-12 | Upgrade | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| Oct-01-09 | Upgrade | Merriman | Sell → Neutral |
| May-29-09 | Downgrade | Hapoalim | Neutral → Underperform |
| May-29-09 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| Dec-15-08 | Initiated | Merriman Curhan Ford | Buy |
| Nov-28-07 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jan-31-07 | Initiated | Stifel Nicolaus | Buy |
| Jan-05-07 | Initiated | First Albany | Buy |
View All
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
Sanctuary Advisors LLC Has $1.24 Million Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates - MSN
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Catalyst Pharmaceuticals (NASDAQ:CPRX) Shares Gap UpHere's What Happened - MarketBeat
Catalyst Pharmaceuticals' (CPRX) "Overweight" Rating Reaffirmed at Stephens - MarketBeat
Oppenheimer Adjusts Price Target on Catalyst Pharmaceuticals to $32 From $31, Maintains Outperform Rating - Marketscreener.com
Ieq Capital LLC Invests $313,000 in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Principal Financial Group Inc. Grows Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Earnings call transcript: Catalyst Pharmaceuticals Q4 2024 beats expectations By Investing.com - Investing.com Australia
Catalyst Pharmaceuticals Inc (CPRX) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Catalyst Pharmaceuticals Reports Record 2024 Financial Results - TipRanks
Catalyst Pharmaceuticals Reports Strong Growth Amid Challenges - TipRanks
Catalyst Pharmaceuticals (NASDAQ:CPRX) Announces Quarterly Earnings Results - MarketBeat
Catalyst Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today - MSN
Catalyst Pharmaceuticals Inc (CPRX) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Catalyst Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Earnings call transcript: Catalyst Pharmaceuticals Q4 2024 beats expectations - Investing.com
Catalyst Pharma Forecasts Double-Digit Revenue Growth For 2025 - RTTNews
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Position Increased by Rhumbline Advisers - Defense World
Investor Network: Catalyst Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Catalyst Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Catalyst Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Earnings Flash (CPRX) Catalyst Pharmaceuticals Reports Q4 Revenue $141.8M, vs. FactSet Est of $134.2M - Marketscreener.com
Catalyst Pharmaceuticals Reports Record Fourth Quarter and - GlobeNewswire
How Catalyst's Three-Product Strategy Drove 23.5% Revenue Growth to Record $491.7M in 2024 - StockTitan
CATALYST PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
Sanctuary Advisors LLC Has $1.24 Million Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Catalyst Pharmaceuticals Inc (CPRX) Q4 2024: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Brokerages Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) PT at $32.25 - Defense World
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Cautious Investors Not Rewarding Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Performance Completely - Simply Wall St
Allspring Global Investments Holdings LLC Boosts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stake Raised by Allspring Global Investments Holdings LLC - Defense World
Catalyst Pharmaceuticals (CPRX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Allspring Global Investments Holdings LLC Has $8.71 Million Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Catalyst Pharmaceuticals stock hits all-time high of $24.44 - MSN
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Those who invested in Catalyst Pharmaceuticals (NASDAQ:CPRX) five years ago are up 374% - Yahoo Finance
Yousif Capital Management LLC Has $903,000 Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Advisors Preferred LLC Takes $1.08 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025 - GlobeNewswire
Catalyst Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025 - Nasdaq
Earnings Alert: Catalyst Pharmaceuticals Sets Key Q4 Financial Results DateStrategic Updates Expected - StockTitan
abrdn plc Acquires Shares of 484,666 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by Spire Wealth Management - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Raised to "Strong-Buy" at Baird R W - MarketBeat
Short Interest in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Rises By 12.5% - MarketBeat
Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):